Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -43.11% is 68% below its 5-year average of -25.66%, near the low end of its 5-year range (-43.11%–-7.29%).
As of the fiscal period ended Tuesday, June 30, 2026. 11.32% below its 12-month average of -38.73%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -43.11%.
RETURN ON EQUITY (ROE)
-43.11%
RETURN ON EQUITY (ROE) AVG TTM
-38.73%
RETURN ON EQUITY (ROE) AVG 3Y
-32.05%
RETURN ON EQUITY (ROE) AVG 5Y
-25.66%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-11.32%
CURRENT VS 3Y AVG
-34.50%
CURRENT VS 5Y AVG
-67.99%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 681 covered companies
CURRENT VS SECTOR MEDIAN
-5.79%
vs the sector median at left
Nautilus Biotechnolgy, Inc.
Market Cap
$240.26M
Return on Equity (ROE)
-43.11%
TTM Avg
-38.73%
3Y Avg
-32.05%
5Y Avg
-25.66%
Market Cap
$242.31M
Return on Equity (ROE)
N/A
TTM Avg
-1340.59%
3Y Avg
-55.32%
5Y Avg
-61.68%
Market Cap
$242.27M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
Market Cap
$242.23M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$242.02M
Return on Equity (ROE)
N/A
TTM Avg
35.05%
3Y Avg
64.68%
5Y Avg
-167.54%
Market Cap
$245.55M
Return on Equity (ROE)
31.90%
TTM Avg
-385.06%
3Y Avg
-191.20%
5Y Avg
-142.10%
Market Cap
$245.30M
Return on Equity (ROE)
-54.67%
TTM Avg
-46.45%
3Y Avg
-41.29%
5Y Avg
-47.75%
Market Cap
$238.90M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
Market Cap
$238.48M
Return on Equity (ROE)
-1.67%
TTM Avg
19.58%
3Y Avg
23.42%
5Y Avg
29.49%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $240.26M | -43.11% | -38.73% | -32.05% | -25.66% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.31M | N/A | -1340.59% | -55.32% | -61.68% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.27M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.23M | N/A | -125.28% | -42.20% | -43.41% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.02M | N/A | 35.05% | 64.68% | -167.54% |
| Q32 Bio Inc. (QTTB)vs › | $245.55M | 31.90% | -385.06% | -191.20% | -142.10% |
| Quantum-Si incorporated (QSI)vs › | $245.30M | -54.67% | -46.45% | -41.29% | -47.75% |
| Invivyd, Inc. (IVVD)vs › | $238.90M | -59.27% | -136.66% | -113.26% | -53.68% |
| SIGA Technologies, Inc. (SIGA)vs › | $238.48M | -1.67% | 19.58% | 23.42% | 29.49% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.60M | -118.58% | 62.37% | -376.78% | -340.60% |
ROE
-43.1%
ROA
-34.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -43.11% |
| 2026-03-31 | -39.53% |
| 2025-12-31 | -37.59% |
| 2025-09-30 | -37.14% |
| 2025-06-30 | -36.27% |
| 2025-03-31 | -35.31% |
| 2024-12-31 | -33.91% |
| 2024-09-30 | -31.42% |
| 2024-06-30 | -29.60% |
| 2024-03-31 | -27.03% |
| 2023-12-31 | -24.00% |
| 2023-09-30 | -21.66% |
| 2023-06-30 | -20.11% |
| 2023-03-31 | -18.81% |
| 2022-12-31 | -18.39% |
| 2022-09-30 | -18.81% |
| 2022-06-30 | -18.26% |
| 2022-03-31 | -16.49% |
| 2021-12-31 | -13.84% |
| 2021-09-30 | -10.32% |
| 2021-06-30 | -7.29% |
| 2021-03-31 | -29.45% |
| 2020-09-30 | -6.79% |
| 2019-12-31 | 14.28% |
